ClinicalTrials.gg
TerminatedNCT03203447TOPAZUpdated Apr 23, 2021Results posted

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

A Phase 3 interventional study of suprachoroidal CLS-TA and suprachoroidal sham in Macular Edema and Retinal Vein Occlusion, sponsored by Clearside Biomedical, Inc.. Terminated at 92 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-23.

Sponsored by Clearside Biomedical, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
The early termination is due to the results obtained from the sister study, SAPPHIRE (CLS1003-301), which did not meet the 8-week primary efficacy endpoint.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.

Enrollment
5th of 25
325 · median 75
Started
2018
the only one that year
Phase 3
8 of 26
none open now
Registered
20th of 26
by date
Lead sponsor
2 of 26
Clearside Biomedical, Inc.

Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2018, is one of 8 in phase 3, and was the 20th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing Triamcinolone Acetonide in Macular Edema, or all of them as a file.
02

Study summary

This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO is superior to IVT anti-VEGF agent used alone.

Read the detailed description

A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Anti-VEGF Agent in Subjects With Retinal Vein Occlusion

03

Conditions studied

  • Macular Edema
  • Retinal Vein Occlusion

Keywords

  • RVO
  • ME
  • Microneedle
  • Microinjection
  • Triamcinolone
  • Choroid
  • Choroid injection
  • Suprachoroidal
  • Anti-VEGF
  • Subretinal Fluid
  • Cystoid Macular Edema
  • Optical Coherence Tomography
  • OCT
  • Central Subfield Thickness
  • Lucentis
  • Avastin
  • Ranibizumab
  • Bevacizumab
  • Triamcinolone acetonide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a clinical diagnosis of RVO in the study eye
  • Has a CST of ≥ 300 µm in the study eye
  • Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye
  • Is naïve to local pharmacologic treatment for RVO in the study eye

Exclusion criteria

Exclusion Criteria:

  • Any active ocular disease or infection in the study eye other than RVO
  • History of glaucoma, intraocular pressure > 21 mmHg or ocular hypertension requiring more than one medication
  • Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study
  • Any evidence of neovascularization in the study eye
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
325 participants (actual)

Study arms

  • Active comparator
    Active

    Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection

    Drug: suprachoroidal CLS-TA · Drug: Lucentis or Avastin

  • Sham comparator
    Control

    Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure

    Drug: suprachoroidal sham · Drug: Lucentis or Avastin

Interventions

  • suprachoroidal injection of CLS-TA

    Also known as: Triamcinolone acetonide

  • Drugsuprachoroidal sham

    sham suprachoroidal procedure

  • DrugLucentis or Avastin

    IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin

    Also known as: IVT anti-VEGF agent

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)

    Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.

    Time frame: 2 months

Secondary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity

    Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

    Time frame: 6 months

  2. Mean Change From Baseline in Central Subfield Thickness

    Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

    Time frame: 6 months

07

Results

Posted Apr 23, 2021
Limitations and caveats
Due to the early termination of the trial by sponsor, 325 of the planned 460 were enrolled. All planned study visits were not completed by all treated subjects; therefore, all planned data was not collected.

Participant flow

Participant flow — Overall Study
MilestoneActiveControl
Started162163
Completed00
Not completed162163
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up110
Withdrew: Includes premature discontinuation due to study termination and unknown159152

Outcome measures

PrimaryProportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)

Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.

Time frame:
2 months
Reported as:
Count of participants · Participants
Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
ParticipantsActiveControl
Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)6476
Statistical analysis
  • Active vs Control · Cochran-Mantel-Haenszel · p = 0.191 (The a priori threshold for statistical significance was 0.050. Prior to evaluating the results of the CMH test, a Breslow-Day test with Tarone's adjustment was conducted to confirm the homogeneity of the odds ratios between RVO strata.) · Difference in percentages: -7.1 · 95% CI -17.9 to 3.6Estimated value was calculated as the percentage of subjects in the Active arm meeting the primary endpoint minus the percentage of subjects in the Control arm meeting the primary endpoint.
SecondaryMean Change From Baseline in Best Corrected Visual Acuity

Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

Time frame:
6 months
Reported as:
Least squares mean · letters
Mean Change From Baseline in Best Corrected Visual Acuity
lettersActiveControl
Mean Change From Baseline in Best Corrected Visual Acuity13.8 ± 1.9620.7 ± 1.91
SecondaryMean Change From Baseline in Central Subfield Thickness

Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

Time frame:
6 months
Reported as:
Least squares mean · microns
Mean Change From Baseline in Central Subfield Thickness
micronsActiveControl
Mean Change From Baseline in Central Subfield Thickness-353.6 ± 19.60-374.7 ± 19.12

Adverse events

Collected over Adverse events were collected through follow-up and study completion, approximately 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active0/160 (0%)1/160 (0.6%)11/160 (6.9%)
Control0/162 (0%)3/162 (1.9%)1/162 (0.6%)
Most frequent serious events
Most frequent serious events
EventActiveControl
Cardiac failure congestiveCardiac disorders1/1600/162
Respiratory failureRespiratory, thoracic and mediastinal disorders1/1600/162
Abdominal pain upperGastrointestinal disorders0/1601/162
Urinary tract infectionInfections and infestations0/1601/162
HyperglycaemiaMetabolism and nutrition disorders0/1601/162
Mental status changesPsychiatric disorders0/1601/162
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1601/162
Deep vein thrombosisVascular disorders0/1601/162
Most frequent other events
Most frequent other events
EventActiveControl
Intraocular pressure increasedInvestigations11/1601/162

Baseline characteristics

The Safety population included all randomly assigned subjects who were administered at least one dose of the study drug.

Age, Categorical
Age, Categorical(Participants)ActiveControlTotal
<=18 years000
Between 18 and 65 years7591166
>=65 years8571156
Age, Continuous
Age, Continuous(years)ActiveControlTotal
Mean63.8 ± 13.0762.6 ± 12.2663.2 ± 12.66
Sex: Female, Male
Sex: Female, Male(Participants)ActiveControlTotal
Female7993172
Male8169150
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ActiveControlTotal
American Indian or Alaska Native000
Asian7270142
Native Hawaiian or Other Pacific Islander123
Black or African American639
White7784161
More than one race213
Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(Participants)ActiveControlTotal
Hungary202
United States9698194
Australia235
India6061121
Type of Retinal Vein Occlusion
Type of Retinal Vein Occlusion(Participants)ActiveControlTotal
Branch retinal vein occlusion9093183
Central retinal vein occlusion7069139
08

Study locations

92 sites
  • Retinal Research Institute
    Phoenix, Arizona 85053, United States
  • Retina Centers PC
    Tucson, Arizona 85704, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85710, United States
  • Win Retina
    Arcadia, California 91006, United States
  • Retina Vitreous Medical Group
    Beverly Hills, California 90211, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Macula and Retina Institute
    Glendale, California 91203, United States
  • American Institute of Research
    Los Angeles, California 90017, United States
  • Retina Vitreous Associates Medical Group Inc
    Mountain View, California 94040, United States
  • Stanford University - Byers Eye Institute
    Palo Alto, California 94303, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Retina Consultants Medical Group Inc
    Sacramento, California 95819, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Retina Group of New England, PC
    New London, Connecticut 06320, United States
  • Florida Eye Microsurgical Institute
    Boynton Beach, Florida 33426, United States
  • Specialty Retina Center
    Coral Springs, Florida 33067, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Center for Retina Care at The Eye Institute
    Melbourne, Florida 32904, United States
  • Florida Retina Institute
    Orlando, Florida 32806, United States
  • Eye Associates of Pinellas
    Pinellas Park, Florida 33782, United States
  • Retina Vitreous Associates of Florida
    Saint Petersburg, Florida 33711, United States
  • East Florida Eye Institute EFEI
    Stuart, Florida 34994, United States
  • Southern Vitreoretinal Association
    Tallahassee, Florida 32308, United States
  • Center for Retina And Macular Disease
    Winter Haven, Florida 33880, United States
  • Retina Consultants of Hawaii
    'Aiea, Hawaii 96701, United States
  • Gailey Eye Clinic
    Bloomington, Illinois 61704, United States
  • University and Macula Associates
    Oak Forest, Illinois 60452, United States
  • Prairie Eye Center, Ltd.
    Springfield, Illinois 62704, United States
  • Sabates Eye Centers
    Leawood, Kansas 66211, United States
  • Vitreo-Retinal Consultants and Surgeons PA
    Wichita, Kansas 67214, United States
  • Central Plains Eye MDs
    Wichita, Kansas 67226, United States
  • Paducah Retinal Center
    Paducah, Kentucky 42001, United States
  • Retina Specialists
    Baltimore, Maryland 21204, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • The National Retina Institute
    Towson, Maryland 21204, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • New England Retina Consultants
    Springfield, Massachusetts 01107, United States
  • Associated Retinal Consultants PC
    Grand Rapids, Michigan 49546, United States
  • Vitreo-Retinal Associates, P.C.
    Grand Rapids, Michigan 49546, United States
  • Associated Retinal Consultants P.C.
    Royal Oak, Michigan 48073, United States
  • Retina Consultants of Michigan
    Southfield, Michigan 48034, United States
  • Associated Retinal Consultants PC
    Traverse City, Michigan 49686, United States
  • Retina Associates of St. Louis
    Florissant, Missouri 63031, United States
  • Retina Consultants of Nevada
    Las Vegas, Nevada 89144, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Ophthalmic Consultants of Long Island
    Lynbrook, New York 11563, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • Island Retina
    Shirley, New York 11967, United States
  • Retina-Vitreous Surgeons of Central New York
    Syracuse, New York 13224, United States
  • Retina Associates of Cleveland Inc
    Middleburg Heights, Ohio 44130, United States
  • Dean A. McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Pennsylvania Retina Specialists PC
    Camp Hill, Pennsylvania 17011, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Texas Retina Associates - Arlington
    Arlington, Texas 76012, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Research Center
    Austin, Texas 78705, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina and Vitreous of Texas, PLLC
    Houston, Texas 77025, United States
  • Retina Consultants of Houston, PA
    Houston, Texas 77030, United States
  • Valley Retina Institute, PA
    McAllen, Texas 78503, United States
  • Retina Specialists
    Plano, Texas 75093, United States
  • San Antonio Eye Center
    San Antonio, Texas 78215, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retina Associates of South Texas PA
    San Antonio, Texas 78240, United States
  • Retina Consultants of Houston, PA
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Rocky Mountain Retina Consultants
    Salt Lake City, Utah 84107, United States
  • Retina Group of Washington
    Fairfax, Virginia 22031, United States
  • West Virginia University Medicine Eye Institute
    Morgantown, West Virginia 26506, United States
  • Eye Clinic Albury Wodonga
    Albury, New South Wales 2640, Australia
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Save Sight Institute, University of Sydney (Sydney Eye Hospital)
    Sydney, New South Wales 2000, Australia
  • MH EK Honvédkórház
    Budapest, 1062, Hungary
  • Raghudeep Eye Hospital
    Gujrat, Ahmedabad 380052, India
  • LV Prasad Eye Institute
    Hyderabad, Andhra Pradesh 500034, India
  • L V Prasad Eye Institute
    Visakhapatnam, Andhra Pradesh 530040, India
  • R.P. Centre, AIIMS
    New Delhi, Ansari Nagar 110029, India
  • Narayana Nethralaya
    RajajiNagar, Bangalaore 560010, India
  • LV Prasad Eye Institute
    Patia, Bhubaneswar 751024, India
  • M&J Western Regional Institute of Ophthalmology
    Asarwa, Gujarat 380016, India
  • PBMA's H.V Desai Eye Hospital
    Pune, Maharashtra 411060, India
  • Dr Shroff 's Charity Eye Hospital
    Delhi, New Delhi 758770, India
  • Regional Institute of Ophthalmology
    Bihar, Patna 800001, India
  • B B Eye Foundation VIP
    Kolkata, Raghunathpur 700059, India
  • SMS Hospital
    Jaipur, Rajasthan 302004, India
  • Aravind Eye Hospital
    Madurai, Tamil Nadu 625020, India
  • Jawaharlal Rohatgi Eye Hospital
    Kanpur, Uttar Pradesh 208005, India
  • Disha Eye Hospitals Pvt. Ltd.
    Kolkata, West Bengal 700120, India
  • Auckland Eye
    Auckland, 1050, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Dec 2018, 9 months.

Results were first posted in Apr 2021, 2 years 4 months after primary completion. A results delay was requested in Dec 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2017
First posted
Jun 29, 2017
StartActual
Mar 5, 2018
Primary completionActual
Dec 18, 2018
CompletionActual
Dec 18, 2018
Results delay requested
Dec 13, 2019
Results first posted
Apr 23, 2021
Last update
Apr 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03203447
Lead sponsor
Clearside Biomedical, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2017
Start date
Mar 5, 2018
Primary completion
Dec 18, 2018
Completion
Dec 18, 2018
Results posted
Apr 23, 2021
Last update
Apr 23, 2021

Study contacts

Thomas Ciulla, MD
study director · Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion